{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T21:32:08Z","timestamp":1794605528199,"version":"4.9.1"},"reference-count":86,"publisher":"Elsevier","isbn-type":[{"value":"9780128166680","type":"print"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1016\/bs.apha.2019.06.001","type":"book-chapter","created":{"date-parts":[[2019,7,13]],"date-time":"2019-07-13T07:26:01Z","timestamp":1563002761000},"page":"273-305","source":"Crossref","is-referenced-by-count":36,"title":["Positive allosteric modulators of the dopamine D1 receptor: A new mechanism for the treatment of neuropsychiatric disorders"],"prefix":"10.1016","author":[{"given":"Kjell A.","family":"Svensson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junliang","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F.","family":"Bruns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1\u20132","key":"10.1016\/bs.apha.2019.06.001_bb0010","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0006-8993(00)02298-8","article-title":"D1 dopamine receptor activation reduces extracellular glutamate and GABA concentrations in the medial prefrontal cortex","volume":"867","author":"Abekawa","year":"2000","journal-title":"Brain Research"},{"issue":"3","key":"10.1016\/bs.apha.2019.06.001_bb0015","first-page":"166","article-title":"Probing cortical dopamine function in schizophrenia: What can D1 receptors tell us","volume":"2","author":"Abi-Dargham","year":"2003","journal-title":"World Psychiatry"},{"issue":"2","key":"10.1016\/bs.apha.2019.06.001_bb0020","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.bbr.2008.12.010","article-title":"The role of histamine on cognition","volume":"199","author":"Alvarez","year":"2009","journal-title":"Behavioural Brain Research"},{"issue":"1","key":"10.1016\/bs.apha.2019.06.001_bb0025","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF00426210","article-title":"Effects of scopolamine, d-amphetamine and other drugs affecting catecholamines on spontaneous alternation and locomotor activity in mice","volume":"45","author":"Anisman","year":"1975","journal-title":"Psychopharmacologia"},{"key":"10.1016\/bs.apha.2019.06.001_bb0030","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1093\/cercor\/bht195","article-title":"The neurobiology of thought: The groundbreaking discoveries of Patricia Goldman-Rakic 1937\u20132003","volume":"123","author":"Arnsten","year":"2013","journal-title":"Cerebral Cortex"},{"issue":"1","key":"10.1016\/bs.apha.2019.06.001_bb0035","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.biopsych.2015.12.028","article-title":"Novel dopamine therapeutics for cognitive deficits in schizophrenia","volume":"81","author":"Arnsten","year":"2017","journal-title":"Biological Psychiatry"},{"issue":"7","key":"10.1016\/bs.apha.2019.06.001_bb0040","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1038\/oby.2007.205","article-title":"Randomized controlled trials of the D1\/D5 antagonist ecopipam for weight loss in obese subjects","volume":"15","author":"Astrup","year":"2007","journal-title":"Obesity"},{"key":"10.1016\/bs.apha.2019.06.001_bb0045","series-title":"3,4-Dihydroisoquinolin-2 (1h)-yl compounds","author":"Beadle","year":"2014"},{"issue":"1","key":"10.1016\/bs.apha.2019.06.001_bb0050","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1124\/pr.110.002642","article-title":"The physiology, signaling, and pharmacology of dopamine receptors","volume":"63","author":"Beaulieu","year":"2011","journal-title":"Pharmacological Reviews"},{"issue":"1","key":"10.1016\/bs.apha.2019.06.001_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/lm.68004","article-title":"Acetylcholine, histamine, and cognition: Two sides of the same coin","volume":"11","author":"Blandina","year":"2004","journal-title":"Learning & Memory"},{"issue":"3","key":"10.1016\/bs.apha.2019.06.001_bb0060","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/j.1471-4159.1987.tb05591.x","article-title":"Modulation of in vivo dopamine release by D2 but not D1 receptor agonists and antagonists","volume":"48","author":"Boyar","year":"1987","journal-title":"Journal of Neurochemistry"},{"issue":"5","key":"10.1016\/bs.apha.2019.06.001_bb0065","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/00002826-199310000-00002","article-title":"Neurobiological mechanisms involved in antidepressant therapies","volume":"16","author":"Briley","year":"1993","journal-title":"Clinical Neuropharmacology"},{"key":"10.1016\/bs.apha.2019.06.001_bb0070","first-page":"939","article-title":"Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes","volume":"38","author":"Bruns","year":"1990","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/bs.apha.2019.06.001_bb0075","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.neuropharm.2017.10.032","article-title":"Preclinical profile of a dopamine D1 potentiator suggests therapeutic utility in neurological and psychiatric disorders","volume":"128","author":"Bruns","year":"2018","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/bs.apha.2019.06.001_bb0080","first-page":"1","article-title":"Treatment of cognitive deficits in Alzheimer's disease: A psychopharmacological review","volume":"28","author":"Campos","year":"2016","journal-title":"Psychiatria Danubina"},{"issue":"4596","key":"10.1016\/bs.apha.2019.06.001_bb0085","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/1801200a0","article-title":"3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists","volume":"180","author":"Carlsson","year":"1957","journal-title":"Nature"},{"key":"10.1016\/bs.apha.2019.06.001_bb9000","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1126\/science.127.3296.471","article-title":"On the presence of 3-hydroxytyramine in brain","volume":"127","author":"Carlsson","year":"1958","journal-title":"Science"},{"issue":"6","key":"10.1016\/bs.apha.2019.06.001_bb0090","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1523\/JNEUROSCI.3987-03.2004","article-title":"Enhancement of working memory in aged monkeys by a sensitizing regimen of dopamine D1 receptor stimulation","volume":"24","author":"Castner","year":"2004","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/bs.apha.2019.06.001_bb0095","article-title":"The dopamine D1 receptor positive allosteric modulator DPTQ enhances spontaneous eye blink rate and spatial working memory in the rhesus monkey","author":"Castner","year":"2019"},{"issue":"3","key":"10.1016\/bs.apha.2019.06.001_bb0100","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1474-4422(06)70373-8","article-title":"Non-motor symptoms of Parkinson's disease: Diagnosis and management","volume":"5","author":"Chaudhuri","year":"2006","journal-title":"The Lancet. Neurology"},{"issue":"2","key":"10.1016\/bs.apha.2019.06.001_bb0105","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1124\/pr.54.2.323","article-title":"G protein-coupled receptor allosterism and complexing","volume":"54","author":"Christopoulos","year":"2002","journal-title":"Pharmacological Reviews"},{"issue":"2","key":"10.1016\/bs.apha.2019.06.001_bb0110","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0014-2999(90)90456-G","article-title":"Dopamine D1 receptor stimulation increases striatal acetylcholine release in the rat","volume":"186","author":"Damsma","year":"1990","journal-title":"European Journal of Pharmacology"},{"issue":"2","key":"10.1016\/bs.apha.2019.06.001_bb0115","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1001\/archpsyc.1990.01810140090014","article-title":"Effects of the D-1 agonist SKF-38393 combined with haloperidol in schizophrenic patients","volume":"47","author":"Davidson","year":"1990","journal-title":"Archives of General Psychiatry"},{"issue":"24","key":"10.1016\/bs.apha.2019.06.001_bb0120","doi-asserted-by":"crossref","first-page":"11384","DOI":"10.1021\/acs.jmedchem.8b01622","article-title":"Discovery and lead optimization of atropisomer D1 agonists with reduced desensitization","volume":"61","author":"Davoren","year":"2018","journal-title":"Journal of Medicinal Chemistry"},{"issue":"3","key":"10.1016\/bs.apha.2019.06.001_bb0125","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/0306-4522(93)90235-8","article-title":"Dopaminergic regulation of cortical acetylcholine release: Effects of dopamine receptor agonists","volume":"54","author":"Day","year":"1993","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/bs.apha.2019.06.001_bb0130","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00228-013-1600-y","article-title":"Long-term neurocognitive effects of antipsychotics in schizophrenia: A network meta-analysis","volume":"70","author":"D\u00e9sam\u00e9ricq","year":"2014","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"3","key":"10.1016\/bs.apha.2019.06.001_bb0135","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/jnnp.64.3.320","article-title":"Spontaneous and reflex activity of facial muscles in dystonia, Parkinson's disease, and in normal subjects","volume":"64","author":"Deuschl","year":"1998","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"3","key":"10.1016\/bs.apha.2019.06.001_bb0140","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/da.20168","article-title":"Decreased striatal D1 binding as measured using PET and [11C]SCH 23,390 in patients with major depression with anger attacks","volume":"23","author":"Dougherty","year":"2006","journal-title":"Depression and Anxiety"},{"issue":"4","key":"10.1016\/bs.apha.2019.06.001_bb0145","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0022-3956(03)00007-4","article-title":"Selective alterations of the first NREM sleep cycle in humans by a dopamine D1 receptor antagonist (NNC-687)","volume":"37","author":"Eder","year":"2003","journal-title":"Journal of Psychiatric Research"},{"issue":"24","key":"10.1016\/bs.apha.2019.06.001_bb0150","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa041470","article-title":"Rivastigmine for dementia associated with Parkinson's disease","volume":"351","author":"Emre","year":"2004","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"10.1016\/bs.apha.2019.06.001_bb0155","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0166-4328(88)90157-X","article-title":"A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data","volume":"31","author":"Ennaceur","year":"1988","journal-title":"Behavioural Brain Research"},{"key":"10.1016\/bs.apha.2019.06.001_bb0160","first-page":"22","article-title":"Allosteric modulation: A novel approach to drug discovery","volume":"24","author":"Epping-Jordan","year":"2007","journal-title":"Innovations in Pharmaceutical Technology"},{"issue":"1","key":"10.1016\/bs.apha.2019.06.001_bb0165","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1124\/jpet.110.172957","volume":"336","author":"Fell","year":"2011","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"3","key":"10.1016\/bs.apha.2019.06.001_bb0170","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1527-3458.2001.tb00201.x","article-title":"Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: Preclinical pharmacology and clinical data","volume":"7","author":"Giardina","year":"2001","journal-title":"CNS Drug Reviews"},{"issue":"1","key":"10.1016\/bs.apha.2019.06.001_bb0175","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00213-004-1793-y","article-title":"Targeting the dopamine D1 receptor in schizophrenia: Insights for cognitive dysfunction","volume":"174","author":"Goldman-Rakic","year":"2004","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/bs.apha.2019.06.001_bb0180","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0165-0173(99)00045-4","article-title":"D1 receptors in prefrontal cells and circuits","volume":"31","author":"Goldman-Rakic","year":"2000","journal-title":"Brain Research Reviews"},{"issue":"1","key":"10.1016\/bs.apha.2019.06.001_bb0185","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/s41467-017-02776-7","article-title":"Impaired \u03b2-arrestin recruitment and reduced desensitization by non-catechol agonists of the D1 dopamine receptor","volume":"9","author":"Gray","year":"2018","journal-title":"Nature Communications"},{"key":"10.1016\/bs.apha.2019.06.001_bb0190","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06649751, an oral dopamine D1\/D5 agonist, in Parkinson's disease: A single ascending dose study","volume":"46","author":"Gray","year":"2018","journal-title":"Parkinsonism & Related Disorders"},{"issue":"2","key":"10.1016\/bs.apha.2019.06.001_bb0195","first-page":"338","article-title":"Dinapsoline: Characterization of a D1 dopamine receptor agonist in a rat model of Parkinson's disease","volume":"296","author":"Gulwadi","year":"2001","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"1","key":"10.1016\/bs.apha.2019.06.001_bb0200","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1021\/acs.jmedchem.8b01767","article-title":"Novel strategies to activate the dopamine D1 receptor: Recent advances in orthosteric agonism and positive allosteric modulation","volume":"62","author":"Hall","year":"2019","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/bs.apha.2019.06.001_bb0205","article-title":"The discovery of novel dopamine D1 positive allosteric modulators for the treatment of neurodegenerative disorders","author":"Hembre","year":"2018"},{"issue":"2","key":"10.1016\/bs.apha.2019.06.001_bb0210","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0169-328X(00)00015-2","article-title":"Dopamine D-5 receptor modulates hippocampal acetylcholine release","volume":"76","author":"Hersi","year":"2000","journal-title":"Molecular Brain Research"},{"key":"10.1016\/bs.apha.2019.06.001_bb0215","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.bbr.2012.09.030","article-title":"D1 receptor agonists reverse the subchronic phencyclidine (PCP)-induced novel object recognition (NOR) deficit in female rats","volume":"238","author":"Horiguchi","year":"2013","journal-title":"Behavioural Brain Research"},{"issue":"1","key":"10.1016\/bs.apha.2019.06.001_bb0220","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejphar.2006.11.048","article-title":"Methylphenidate and atomoxetine increase histamine release in rat prefrontal cortex","volume":"558","author":"Horner","year":"2007","journal-title":"European Journal of Pharmacology"},{"issue":"1","key":"10.1016\/bs.apha.2019.06.001_bb0225","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/jpet.103.053918","article-title":"Wake-promoting actions of dopamine D1 and D2 receptor stimulation","volume":"307","author":"Isaac","year":"2003","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"2","key":"10.1016\/bs.apha.2019.06.001_bb0230","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0304-3940(03)00006-5","article-title":"Modafinil increases histamine release in the anterior hypothalamus of rats","volume":"339","author":"Ishizuka","year":"2003","journal-title":"Neuroscience Letters"},{"issue":"5","key":"10.1016\/bs.apha.2019.06.001_bb0235","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.tins.2007.03.002","article-title":"Dopamine: 50 Years in perspective","volume":"30","author":"Iversen","year":"2007","journal-title":"Trends in Neurosciences"},{"issue":"3","key":"10.1016\/bs.apha.2019.06.001_bb0240","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1124\/jpet.104.071092","article-title":"Effects of dopamine D1 ligands on eye blinking in monkeys: Efficacy, antagonism, and D1\/D2 interactions","volume":"311","author":"Jutkiewicz","year":"2004","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"1","key":"10.1016\/bs.apha.2019.06.001_bb0245","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1756-6606-5-14","article-title":"The molecular biology of memory: cAMP, PKA, CRE, CREB-1, CREB-2, and CPEB","volume":"5","author":"Kandel","year":"2012","journal-title":"Molecular Brain"},{"issue":"6","key":"10.1016\/bs.apha.2019.06.001_bb0250","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/ana.410120614","article-title":"Blink rates in Parkinsonism","volume":"12","author":"Karson","year":"1982","journal-title":"Annals of Neurology"},{"issue":"2","key":"10.1016\/bs.apha.2019.06.001_bb0255","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000341998","article-title":"Cognitive impairment in Parkinson's disease: The dual syndrome hypothesis","volume":"11","author":"Kehagia","year":"2013","journal-title":"Neurodegenerative Diseases"},{"issue":"6","key":"10.1016\/bs.apha.2019.06.001_bb0260","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1111\/j.1476-5381.2011.01749.x","article-title":"Biased signalling and allosteric machines: New vistas and challenges for drug discovery","volume":"165","author":"Kenakin","year":"2012","journal-title":"British Journal of Pharmacology"},{"issue":"3","key":"10.1016\/bs.apha.2019.06.001_bb9005","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","article-title":"Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: Psychotomimetic, perceptual, cognitive, and neuroendocrine responses","volume":"51","author":"Krystal","year":"1994","journal-title":"Archives of general psychiatry"},{"issue":"9","key":"10.1016\/bs.apha.2019.06.001_bb0265","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/sj.npp.1300467","article-title":"Reduction in acetylcholine release in the hippocampus of dopamine D5 receptor-deficient mice","volume":"29","author":"Laplante","year":"2004","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/bs.apha.2019.06.001_bb0270","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1124\/jpet.115.224071","article-title":"Discovery of D1 dopamine receptor positive allosteric modulators: Characterization of pharmacology and identification of residues that regulate species selectivity","volume":"354","author":"Lewis","year":"2015","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"4","key":"10.1016\/bs.apha.2019.06.001_bb0275","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1124\/mol.118.113175","article-title":"Identification of positive allosteric modulators of the D1 dopamine receptor that act at diverse binding sites","volume":"94","author":"Luderman","year":"2018","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/bs.apha.2019.06.001_bb0280","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.bbr.2018.12.006","article-title":"The allosteric dopamine D1 receptor potentiator, DETQ, ameliorates subchronic phencyclidine-induced object recognition memory deficits and enhances cortical acetylcholine efflux in male humanized D1 receptor knock-in mice","volume":"361","author":"Meltzer","year":"2019","journal-title":"Behavioural Brain Research"},{"issue":"14","key":"10.1016\/bs.apha.2019.06.001_bb0285","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1111\/bph.13509","article-title":"GPCRdb: The G protein-coupled receptor database\u2014An introduction","volume":"173","author":"Munk","year":"2016","journal-title":"British Journal of Pharmacology"},{"issue":"3","key":"10.1016\/bs.apha.2019.06.001_bb0290","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1515\/revneuro-2013-0004","article-title":"Prefrontal dopamine signaling and cognitive symptoms of Parkinson's disease","volume":"24","author":"Narayanan","year":"2013","journal-title":"Reviews in the Neurosciences"},{"issue":"7","key":"10.1016\/bs.apha.2019.06.001_bb0295","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1073\/pnas.95.7.4040","article-title":"Calcimimetics with potent and selective activity on the parathyroid calcium receptor","volume":"95","author":"Nemeth","year":"1998","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"4","key":"10.1016\/bs.apha.2019.06.001_bb0300","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/BF02244374","article-title":"Role of genotype and dopamine receptors in behaviour of inbred mice in a forced swimming test","volume":"105","author":"Nikulina","year":"1991","journal-title":"Psychopharmacology"},{"issue":"5\u20136","key":"10.1016\/bs.apha.2019.06.001_bb0305","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1159\/000492498","article-title":"Evaluation of D1\/D5 partial agonist PF-06412562 in Parkinson's disease following oral administration","volume":"18","author":"Papapetropoulos","year":"2018","journal-title":"Neurodegenerative Diseases"},{"issue":"3","key":"10.1016\/bs.apha.2019.06.001_bb0310","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00213-004-2048-7","article-title":"Forced swimming test in mice: A review of antidepressant activity","volume":"177","author":"Petit-Demouliere","year":"2005","journal-title":"Psychopharmacology"},{"issue":"Suppl. 1","key":"10.1016\/bs.apha.2019.06.001_bb0315","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1468-1331.2008.02056.x","article-title":"Non-motor symptoms in Parkinson's disease","volume":"15","author":"Poewe","year":"2008","journal-title":"European Journal of Neurology"},{"issue":"3","key":"10.1016\/bs.apha.2019.06.001_bb0320","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00213-010-1840-9","article-title":"Amelioration of ketamine-induced working memory deficits by dopamine D1 receptor agonists","volume":"210","author":"Roberts","year":"2010","journal-title":"Psychopharmacology"},{"issue":"10","key":"10.1016\/bs.apha.2019.06.001_bb0325","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1017\/S0033291713002535","article-title":"Cognitive impairment in depression: A systematic review and meta-analysis","volume":"44","author":"Rock","year":"2014","journal-title":"Psychological Medicine"},{"issue":"2","key":"10.1016\/bs.apha.2019.06.001_bb0330","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/npp.2014.192","article-title":"Effects of the D1 dopamine receptor agonist dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder","volume":"40","author":"Rosell","year":"2015","journal-title":"Neuropsychopharmacology"},{"issue":"5594","key":"10.1016\/bs.apha.2019.06.001_bb0335","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1126\/science.1075333","article-title":"Postsynaptic signaling and plasticity mechanisms","volume":"298","author":"Sheng","year":"2002","journal-title":"Science"},{"key":"10.1016\/bs.apha.2019.06.001_bb0340","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1146\/annurev.cellbio.23.090506.123516","article-title":"The cell biology of synaptic plasticity: AMPA receptor trafficking","volume":"23","author":"Shepherd","year":"2007","journal-title":"Annual Review of Cell and Developmental Biology"},{"key":"10.1016\/bs.apha.2019.06.001_bb0345","series-title":"Heterocyclic acetamide compound","author":"Shiraki","year":"2015"},{"issue":"4","key":"10.1016\/bs.apha.2019.06.001_bb0350","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1001\/jamapsychiatry.2014.2414","article-title":"Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: A positron emission tomographic functional magnetic resonance imaging study","volume":"72","author":"Slifstein","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"12","key":"10.1016\/bs.apha.2019.06.001_bb0355","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1111\/j.1460-9568.2007.05952.x","article-title":"Involvement of AMPA receptor phosphorylation in antidepressant actions with special reference to tianeptine","volume":"26","author":"Svenningsson","year":"2007","journal-title":"European Journal of Neuroscience"},{"issue":"1","key":"10.1016\/bs.apha.2019.06.001_bb0360","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1124\/jpet.116.236372","article-title":"An allosteric potentiator of the dopamine D1 receptor increases locomotor activity in human D1 knock-in mice without causing stereotypy or tachyphylaxis","volume":"360","author":"Svensson","year":"2017","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"1","key":"10.1016\/bs.apha.2019.06.001_bb0365","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1124\/mol.111.074872","article-title":"Probe dependence in the allosteric modulation of a G protein-coupled receptor: Implications for detection and validation of allosteric ligand effects","volume":"81","author":"Valant","year":"2012","journal-title":"Molecular Pharmacology"},{"issue":"3","key":"10.1016\/bs.apha.2019.06.001_bb0370","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/nn1846","article-title":"Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory","volume":"10","author":"Vijayraghavan","year":"2007","journal-title":"Nature Neuroscience"},{"key":"10.1016\/bs.apha.2019.06.001_bb0375","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3389\/fnsys.2012.00072","article-title":"Histamine H3 receptor antagonists\/inverse agonists on cognitive and motor processes: Relevance to Alzheimer's disease, ADHD, schizophrenia, and drug abuse","volume":"6","author":"Vohora","year":"2012","journal-title":"Frontiers in Systems Neuroscience"},{"issue":"2","key":"10.1016\/bs.apha.2019.06.001_bb0380","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1037\/0894-4105.18.2.296","article-title":"Relational integration and executive function in Alzheimer's disease","volume":"18","author":"Waltz","year":"2004","journal-title":"Neuropsychology"},{"issue":"4","key":"10.1016\/bs.apha.2019.06.001_bb0385","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1124\/mol.118.112649","article-title":"Intracellular binding site for a positive allosteric modulator of the dopamine D1 receptor","volume":"94","author":"Wang","year":"2018","journal-title":"Molecular Pharmacology"},{"issue":"7","key":"10.1016\/bs.apha.2019.06.001_bb0390","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1001\/archpsyc.1987.01800190080012","article-title":"Implications of normal brain development for the pathogenesis of schizophrenia","volume":"44","author":"Weinberger","year":"1987","journal-title":"Archives of General Psychiatry"},{"issue":"7","key":"10.1016\/bs.apha.2019.06.001_bb0395","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/archpsyc.1988.01800310013001","article-title":"Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia: III. A new cohort and evidence for a monoaminergic mechanism","volume":"45","author":"Weinberger","year":"1988","journal-title":"Archives of General Psychiatry"},{"issue":"4","key":"10.1016\/bs.apha.2019.06.001_bb0400","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006171","article-title":"The neuropsychological profile of Alzheimer disease","volume":"2","author":"Weintraub","year":"2012","journal-title":"Cold Spring Harbor Perspectives in Medicine"},{"issue":"4","key":"10.1016\/bs.apha.2019.06.001_bb0405","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/syn.10043","article-title":"Evidence for activation of histamine H3 autoreceptors during handling stress in the prefrontal cortex of the rat","volume":"43","author":"Westerink","year":"2002","journal-title":"Synapse"},{"issue":"6","key":"10.1016\/bs.apha.2019.06.001_bb0410","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2165\/00023210-200620060-00004","article-title":"Cognitive deficits and psychosis in Parkinson's disease","volume":"20","author":"Williams-Gray","year":"2006","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1016\/bs.apha.2019.06.001_bb0415","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/gps.1788","article-title":"A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease\u2014Rivastigmine patch versus capsule","volume":"22","author":"Winblad","year":"2007","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"1","key":"10.1016\/bs.apha.2019.06.001_bb0420","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1124\/jpet.116.233627","article-title":"The rapidly acting antidepressant ketamine and the mGlu2\/3 receptor antagonist LY341495 rapidly engage dopaminergic mood circuits","volume":"358","author":"Witkin","year":"2016","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/bs.apha.2019.06.001_bb0425","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1523\/JNEUROSCI.20-16-j0001.2000","article-title":"Golf-alpha mediates dopamine D1 receptor signaling","volume":"20","author":"Zhuong","year":"2000","journal-title":"The Journal of Neuroscience"}],"container-title":["Advances in Pharmacology","Neuropsychotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1054358919300249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1054358919300249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T06:27:56Z","timestamp":1573799276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1054358919300249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9780128166680"],"references-count":86,"URL":"https:\/\/doi.org\/10.1016\/bs.apha.2019.06.001","relation":{},"ISSN":["1054-3589"],"issn-type":[{"value":"1054-3589","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}